Archives
-
SGI-1027, DNMT Inhibition, and Huh7 Apoptosis
2026-08-17
The 2018 study by Sun and colleagues examines how the non-nucleoside DNMT inhibitor SGI-1027 affects Huh7 hepatocellular carcinoma cells. Its principal contribution is showing that reduced viability is associated with mitochondrial apoptosis, reflected by altered Bcl-2 and Bax expression, rather than a significant redistribution of cell-cycle phases.
-
CAF–ANGPTL4–IQGAP1 Signaling in Prostate Cancer
2026-08-17
This study defines a paracrine mechanism in which cancer-associated fibroblasts increase prostate cancer mitochondrial biogenesis and oxidative phosphorylation through an ANGPTL4–IQGAP1–Raf–MEK–ERK–PGC1α axis. The findings connect tumor-microenvironment signaling to reduced chemotherapy sensitivity and nominate IQGAP1-directed strategies, including QGGP-based intervention, for further validation.
-
Protein A/G Magnetic Beads: Practical IP Guide
2026-08-16
Protein A/G Magnetic Beads support antibody capture, immunoprecipitation, co-immunoprecipitation, and chromatin immunoprecipitation from complex biological samples. This guide explains practical setup and controls while defining limits: performance depends on Fc-compatible IgG antibodies and the product is for research use, not diagnostic or medical workflows.
-
DiscoveryProbe FDA-approved Drug Library Workflows
2026-08-15
Turn a clinically annotated compound set into reproducible GPCR, phenotypic, and mechanism-focused screens with practical dilution, control, and follow-up strategies. APExBIO provides a ready-to-screen format that supports drug repositioning screening while helping researchers connect phenotype hits to pharmacological target identification.
-
Hexa His Tag Peptide: Assay Logic Beyond Elution
2026-08-14
The Hexa His tag peptide is more than a competitive elution reagent: it is a tool for separating antibody occupancy from downstream protein analysis. This article explains its mechanism, workflow design, and the assay lessons that can be drawn—carefully—from recent CARMIL membrane-binding research.
-
In Vitro Metrics for Cancer Drug Response
2026-08-14
Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer activity. By separating proliferative arrest from cell killing and considering their timing, the work provides a more precise framework for interpreting in vitro drug-response experiments.
-
PP2A, Autophagy, and Candida Biofilm Resistance
2026-08-13
A 2025 study identifies PP2A, encoded by PPH21, as an upstream regulator of autophagy-associated biofilm formation and drug resistance in Candida albicans. By combining PPH21 deletion, rapamycin-mediated autophagy activation, cellular assays, and an oral infection model, the work links Atg13 and Atg1 regulation to reduced antifungal treatment efficacy.
-
4-Hydroxytamoxifen: Protocol and QC Guide
2026-08-13
4-Hydroxytamoxifen (SKU B6167) is a DMSO-compatible estrogen receptor modulator for controlled in vitro and in vivo research workflows, including cancer, apoptosis, and cardiac myocyte studies. It should not be selected for protocols requiring ethanol or aqueous solubility, and solution handling, vehicle matching, and storage require deliberate control.
-
Neuromedin S (rat): Practical GPCR Assay Guide
2026-08-12
Neuromedin S (rat) provides a defined endogenous peptide agonist input for controlled studies of neuromedin U receptor signaling and GPCR/G protein signaling. This guide covers reconstitution, assay setup, quality control, and troubleshooting, while emphasizing that potency, dosing, and biological relevance must be established in each validated research model.
-
Cy5 TSA Fluorescence System Kit Workflow
2026-08-12
The Cy5 TSA Fluorescence System Kit converts weak HRP activity into a localized far-red signal for immunohistochemistry, immunocytochemistry, and in situ hybridization. This workflow-focused guide shows how to use signal amplification to support rare-target detection and spatial-proteomics sample selection while controlling background, saturation, and assay-to-assay variability.
-
JNK-IN-7 Workflow for Apoptosis Research
2026-08-11
JNK-IN-7 is a covalent, selective JNK inhibitor for connecting c-Jun phosphorylation with pathogen-induced apoptosis and inflammatory signaling. This workflow translates Candida krusei findings into practical cell-based assay designs while emphasizing concentration control, pathway-specific readouts, and troubleshooting.
-
FITC-Concanavalin A (ConA) Conjugate Guide
2026-08-11
FITC-Concanavalin A (ConA) Conjugate, SKU K4413, provides fluorescent detection of α-D-glucose and α-D-mannose residues on glycoproteins and glycolipids in cell, tissue, microscopy, and flow cytometry workflows. It is intended for carbohydrate-binding analysis, not non-carbohydrate targets or assays performed outside the specified storage, light-protection, and stability conditions.
-
Merbromin: Fluorescence and Antiviral Assay Workflows
2026-08-10
Merbromin combines fluorescence-based protein binding analysis with antimicrobial and viral protease screening potential. This practical guide shows how to prepare the reagent, distinguish static quenching from artifacts, build inhibition assays, and interpret translational limitations responsibly.
-
Ziprasidone HCl: From Receptor Tool to GOT1
2026-08-09
Ziprasidone HCl is more than a receptor pharmacology reagent: it is a mechanistically informative probe of GOT1-dependent glutamine metabolism in pancreatic cancer. This guide explains how to design, interpret, and troubleshoot experiments that connect receptor activity with tumor-cell redox biology.
-
Annexin V-FITC apoptosis kit: Lab Guide
2026-08-08
This scenario-driven guide explains how Annexin V-FITC/PI Apoptosis Assay Kit K2003 supports stage-resolved cell-death analysis in flow cytometry and fluorescence microscopy. It covers controls, protocol timing, interpretation, and practical vendor-selection criteria without overstating what the assay can prove mechanistically.